Evidence map›Paper›PMID 28150715›Full record

ArticleScientific reports2017

Epigenetic regulation of nitric oxide synthase 2, inducible (Nos2) by NLRC4 inflammasomes involves PARP1 cleavage.

Carina de Lima Buzzo, Tiago Medina, Laura M Branco, Silvia L Lage, Luís Carlos de Souza Ferreira, Gustavo P Amarante-Mendes, Michael O Hottiger, Daniel D De Carvalho, Karina R Bortoluci

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Host-virus interaction and viral evasion.Cell biology international · 2021
    Review
  10. Article
  11. Review
  12. Article
  13. CD163Clinical & translational immunology · 2020
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.Therapeutic advances in medical oncology · 2018
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Carina de Lima BuzzoCentro de Terapia Celular e Molecular (CTC-Mol) e Departamento de Ciências Biológicas - Universidade Federal de São Paulo, São Paulo, Brazil.
Tiago MedinaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, M5G 2M9, Canada.
Laura M BrancoCentro de Terapia Celular e Molecular (CTC-Mol) e Departamento de Ciências Biológicas - Universidade Federal de São Paulo, São Paulo, Brazil.
Silvia L LageCentro de Terapia Celular e Molecular (CTC-Mol) e Departamento de Ciências Biológicas - Universidade Federal de São Paulo, São Paulo, Brazil.
Luís Carlos de Souza FerreiraDepartamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
Gustavo P Amarante-MendesInstituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo and Instituto de Investigação em Imunologia, Instituto Nacional de Ciência e Tecnologia (INCT-iii), Brazil.
Michael O HottigerDepartment of Molecular Mechanisms of Disease, University of Zurich, Zurich, Switzerland.
Daniel D De CarvalhoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, M5G 2M9, Canada.
Karina R BortoluciCentro de Terapia Celular e Molecular (CTC-Mol) e Departamento de Ciências Biológicas - Universidade Federal de São Paulo, São Paulo, Brazil.
Universidade Federal de São Paulo · BRUniversidade de São Paulo · BRInstituto Nacional de Ciência e Tecnologia em Entomologia Molecular · BRPrincess Margaret Cancer Centre · CAUniversity Health Network · CAUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nitric oxide synthase 2, inducible (Nos2) expression is necessary for the microbicidal activity of macrophages. However, NOS2 over-activation causes multiple inflammatory disorders, suggesting a tight gene regulation is necessary. Using cytosolic flagellin as a model for inflammasome-dependent NOS2 activation, we discovered a surprising new role for NLRC4/caspase-1 axis in regulating chromatin accessibility of the Nos2 promoter. We found that activation of two independent mechanisms is necessary for NOS2 expression by cytosolic flagellin: caspase-1 and NF-κB activation. NF-κB activation was necessary, but not sufficient, for NOS2 expression. Conversely, caspase-1 was necessary for NOS2 expression, but dispensable for NF-κB activation, indicating that this protease acts downstream NF-κB activation. We demonstrated that epigenetic regulation of Nos2 by caspase-1 involves cleavage of the chromatin regulator PARP1 (also known as ARTD1) and chromatin accessibility of the NF-κB binding sites located at the Nos2 promoter. Remarkably, caspase-1-mediated Nos2 transcription and NO production contribute to the resistance of macrophages to Salmonella typhimurium infection. Our results uncover the molecular mechanism behind the constricted regulation of Nos2 expression and open new therapeutic opportunities based on epigenetic activities of caspase-1 against infectious and inflammatory diseases.

Indexed as

Epigenesis, GeneticAnimalsApoptosis Regulatory ProteinsBase SequenceBinding SitesCalcium-Binding ProteinsCaspase 1CytosolFlagellinGene Expression RegulationInflammasomesMiceMice, KnockoutModels, BiologicalMyeloid Differentiation Factor 88NF-kappa BApoptosis Regulatory ProteinsCalcium-Binding ProteinsCaspase 1FlagellinInflammasomesIpaf protein, mouseMyeloid Differentiation Factor 88NF-kappa BNitric Oxide Synthase Type IIParp1 protein, mousePoly (ADP-Ribose) Polymerase-1

Identifiers

PMID28150715
PMCPMC5288713
OpenAlexW2584600220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.